What's Happening?
Delcath Systems, an interventional oncology company, announced that its CHEMOSAT Hepatic Delivery System for Melphalan has been included as a recommended liver-directed regional therapy in the ESMO–EURACAN Clinical Practice Guidelines for Uveal Melanoma.
This inclusion highlights the system's role in treating hepatic-dominant metastatic uveal melanoma (mUM). The CHEMOSAT system, which administers high-dose chemotherapy directly to the liver, is designed to control systemic exposure and minimize side effects. It has been recognized in the National Comprehensive Cancer Network (NCCN) guidelines and is supported by Phase 3 trials demonstrating improved progression-free survival and response rates compared to alternative care.
Why It's Important?
The inclusion of Delcath Systems' CHEMOSAT system in the ESMO–EURACAN guidelines is a significant validation of its effectiveness as a liver-directed therapy for mUM. With up to 90% of mUM patients developing liver metastases, effective treatment options are limited. The recognition of CHEMOSAT in European guidelines underscores its potential to improve patient outcomes and supports its role in multidisciplinary cancer care. This development could enhance Delcath's market position and influence treatment protocols for liver cancers, potentially leading to broader adoption of the CHEMOSAT system in clinical practice.
What's Next?
Delcath Systems is likely to focus on expanding the use of its CHEMOSAT system in both the U.S. and European markets. The company may pursue further clinical trials to explore additional applications of the system in treating other liver-related cancers. As the system gains recognition in clinical guidelines, Delcath may also seek partnerships with healthcare providers and institutions to facilitate its adoption and integration into standard cancer treatment protocols.
